Navigation Links
Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
Date:3/18/2009

ies for the use of the Company's technology to evaluate compounds. This effort resulted in contracts including two with Centocor, Inc.
  • The Company entered into a royalty agreement with Concordia Pharmaceuticals to realize the potential upside value of Salirasib, Concordia's novel compound for the treatment of cancer, in combination with another targeted drug.
  • The Company established collaboration with Gradalis Inc. and Mary Crowley Medical Research Center to develop personalized vaccines for cancer patients through the use of the Biomerk Tumorgraft technology.
  • The Company grew the number of procedures within its Personalized Oncology business by 33% and has initiated processes to make this service more readily available in key international markets.
  • The Company continued to expand initiatives to develop its own drug pipeline. During the quarter numerous candidates were identified, due-diligence was performed, and the Company is currently in negotiations for acquisition or co-development of a number of agents.
  • For more information regarding Champions Biotechnology please visit our web site at www.championsbiotechnology.com.

    About Champions Biotechnology, Inc.

    Champions Biotechnology, Inc. is engaged in the development of advanced preclinical platforms and predictive tumor specific data to enhance and accelerate the value of oncology drugs. The Company's Preclinical Platform is a novel approach based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments (Biomerk Tumorgrafts(TM)) in a manner that preserves the biological characteristics of the original human tumor. Early studies suggest that these Tumorgrafts closely reflect human cancer biology and their response to drugs is predicti
    '/>"/>

    SOURCE Champions Biotechnology, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
    2. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
    3. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
    4. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
    5. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
    6. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
    7. Biotechnology Value Fund Urges Stockholders to Remove and Replace Current Board of Avigen, Inc. in an Effort to Protect and Maximize Stockholder Value
    8. Canadian Government Announces Funding for Leading Biotechnology Firms Project
    9. InNexus Biotechnology Announces New Patents Protecting Novel Cell Penetrating DXL(TM) Antibodies
    10. FDA Provides A Positive Review of InNexus Biotechnology Development Plan for Lead Product
    11. PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprovas Enantiomers of DOTAP Chloride in Immunotherapies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
    (Date:1/22/2015)... 2015   Cypher Genomics, Inc., the leading ... SQNM ), the leading molecular diagnostics company, ... noninvasive prenatal tests (NIPT). Through this agreement, Sequenom ... to advance analysis of clinically-relevant fetal sub-chromosomal variants ...
    (Date:1/22/2015)... Jan. 22, 2015  Derma Sciences, Inc. (Nasdaq: ... on advanced wound care, announces that AMNIOEXCEL® and ... been added to the Premier, Inc. Regenerative Skin ... for the AMNIOEXCEL® and AMNIOMATRIX® product lines, which ...
    (Date:12/24/2014)... DALLAS and NEW YORK , ... a biopharmaceutical company advancing patient care in critical areas, announced ... of common stock, and warrants to purchase up to an ... of $4.00 per share and $.01 per warrant.  The warrants ...
    Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
    ... NanoLogix, Inc. (OTC:,NNLX - News) a nano-biotechnology ... company events:, NanoLogix personnel are manning a ... in Sacramento this week, with the company being,represented ... will be,presenting in the Exhibition Hall today, March ...
    ... With Needle-free Vaccine Technology and ... Bird Flu Clinical Program, Webcast/teleconference ... IRVING, Texas, March 31 Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) ... million, or ($0.90) per basic and,diluted share, for the year ended ...
    ... MONMOUTH JUNCTION, N.J., March 31 Transave, ... inhaled,pharmaceuticals for the site-specific treatment of serious ... an aggregate of $35 million pursuant to,its ... Company,s,Board are Richard Kollender from Quaker BioVentures ...
    Cached Biology Technology:NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update 2NanoLogix Inc. Presents at the National Hydrogen Association Conference & Provides Operations, Management and Director Update 3Carrington Reports 2007 Financial Results 2Carrington Reports 2007 Financial Results 3Carrington Reports 2007 Financial Results 4Carrington Reports 2007 Financial Results 5Carrington Reports 2007 Financial Results 6Carrington Reports 2007 Financial Results 7Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing 2Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing 3
    (Date:1/22/2015)... , Jan. 22, 2015   EyeLock, Inc. , a market ... appointed Steve Gerber to the new role of ... responsible for leading development of mobile platforms and wearable solutions ... success and innovation in the semiconductor industry to his role ...
    (Date:12/22/2014)... 2014 Holiday Season may be the brightest ever for ... the long anticipated floodgates for consumer biometrics may finally ... phones, tablets, and wearable mobile devices that incorporate biometrics ... with nearly 4.8 billion biometric devices by 2020.   ...
    (Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
    Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
    ... entomologists will meet June 16-19, 2013 at the Best Western ... South Dakota as the Entomological Society of America,s North Central ... will include: , Forests pests, such as the ... Agricultural insect pests such as the western corn rootworm, the ...
    ... Paris, France: The group of genetic conditions known as ... always fatal, in the case of affected children at an ... gait, and poor co-ordination of hands, speech and eye movements, ... researchers from France and the US have found a new ...
    ... (June 9, 2013) Researchers at Whitehead Institute have ... the drugs that are used to increase red blood ... including those resulting from trauma, sepsis, malaria, kidney dialysis, ... capable of increasing this protein,s production without causing the ...
    Cached Biology News:Interferon-beta aids balance and movement in mice with spinocerebellar ataxia 7 2Interferon-beta aids balance and movement in mice with spinocerebellar ataxia 7 3Scientists identify potential drug target for treatment-resistant anemias 2
    ... Wash Pack provides optimized blocking and ... Quality Clarifier: Ready-to-use wash solutions have ... APS Coated Slides for Microarrays (Product ... Blocking Buffer: 1L • Microarray Post ...
    Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
    Mouse monoclonal antibody raised against a partial recombinant NEK2. NCBI Entrez Gene ID = NEK2...
    Mouse monoclonal antibody raised against a partial recombinant JRKL. NCBI Entrez Gene ID = JRKL...
    Biology Products: